On the NSE, the stock touched Rs 1,480, gaining about 0.7% from its opening price of Rs 1,470. The move came on the heels of a blockbuster listing that saw the pharmaceutical company enter the public markets at a sharp premium to its issue price.
A thumping listing on Dalal Street
Corona Remedies made a solid start to life as a listed company, debuting at a premium of nearly 38.4% over its IPO price of Rs 1,062. The stock opened at Rs 1,470 on the NSE and Rs 1,452 on the BSE, reflecting strong investor appetite that had already been evident during the IPO process.
The Rs 655 crore public issue, which was entirely an offer for sale, drew overwhelming demand across investor categories. The IPO was subscribed 144.5 times overall, led by exceptionally strong interest from institutional investors. Qualified institutional buyers subscribed to their portion nearly 294 times, while non-institutional investors bid more than 220 times. Retail investors also showed solid participation, subscribing to their quota over 30 times.
Strong demand, clean balance sheet
Although Corona Remedies did not raise fresh capital through the IPO, with all proceeds going to selling shareholders, the company comes to the market with a relatively clean balance sheet and a history of consistent profitability. At the IPO price, the company is valued at around Rs 6,495 crore, implying a post-issue price-to-earnings multiple of about 35 times based on annualised FY26 earnings.The scale of demand underscores the confidence investors have placed in the company’s business model, product portfolio and earnings profile, even as the valuation leaves little room for error by traditional measures.
Business focus and financial track record
Corona Remedies has built a focused pharmaceutical franchise across women’s healthcare, cardiology, pain management, urology and other chronic therapies. Its portfolio spans 71 brands, largely positioned in the mid-market segment of the Indian pharmaceutical market, allowing it to scale volumes while maintaining healthy margins.
The company’s pan-India sales network of more than 2,600 medical representatives across 22 states provides deep reach with doctors and hospitals, particularly in non-metro markets.
Financial performance has been steady and improving. Revenue grew 18% year-on-year in FY25 to Rs 1,202 crore, while profit after tax jumped 65% to Rs 149 crore. For the quarter ended June 2025, the company reported PAT of Rs 46 crore, indicating continued momentum into FY26. Return ratios remain strong, with return on equity at 27.5% and return on capital employed above 41%, supported by disciplined capital allocation and a low debt-to-equity ratio of 0.1.
What should investors watch next?
Anchor investors had committed nearly Rs 195 crore ahead of the IPO, lending additional credibility to the issue and helping set the tone for the strong institutional response during the offering.
Also read: From Cyient to TCS, 49 IT stocks see FII selling amid year-long slump. Do you own any?
From here, longer-term returns will hinge on Corona Remedies’ ability to defend margins, expand its brand portfolio and navigate pricing pressures in India’s highly competitive pharmaceutical landscape. For investors tracking the stock after its eye-catching debut, the key question is whether the fundamentals can keep pace with the optimism now reflected in the share price.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)